濮阳市东方医院可靠(濮阳东方妇科地址) (今日更新中)

President Donald Trump said tonight that he has signed an executive order to shut down the use of Chinese-based social media applications TikTok and WeChat in 45 days.The order specifically prohibits any U.S. transactions with TikTok's parent company, ByteDance, starting on Sept. 20.Trump cited privacy concerns for taking the action against the social media networks.TikTok in particular has gained popularity among younger Americans in recent months for its short, entertaining video clips. The TikTok community has often been critical of Trump. Earlier in the summer, users of TikTok organized by reserving tickets to Trump’s rally in Tulsa, which failed to draw the type of crowds the Trump campaign expected.Trump said in his order that WeChat and TikTok “automatically captures vast swaths of information from its users -- threatens to allow the Chinese Communist Party access to Americans’ personal and proprietary information. In addition, WeChat captures the personal and proprietary information of Chinese nationals visiting the United States, thereby allowing the Chinese Communist Party a mechanism for keeping tabs on Chinese citizens who may be enjoying the benefits of a free society for the first time in their lives.”The Trump administration has complained that the application takes data and is used by the Chinese government."All the things that you care that you want to make sure the Chinese Communist Party doesn’t have, we have a responsibility to make sure that the systems that you’re using don’t give them access to that," US Secretary of State Mike Pompeo said two weeks ago.After Trump first said he would ban TikTok in the US last week, TikTok responded by saying in a post on Twitter, “We’re not planning on going anywhere.”Trump said earlier this week he is open to changing his mind if TikTok is sold to an American company. "But if somebody and whether it's Microsoft or somebody else buys it, that'll be interesting," Trump said. "I did say that, if you buy it, whatever the price is that goes to whoever owns it, because I guess it's China essentially, but more than anything else, I said, a very substantial portion of that price is going to have to come into the treasury of the United States because we're making it possible for this deal to happen." 2313

Dec. 10-14: 10 a.m.-9 p.m.Dec. 15: 10 a.m.-10 p.m.Dec. 16: 11 a.m.-8 p.m.Dec. 17-19: 10 a.m.-9 p.m.Dec. 20-21: 10 a.m.-10 p.m.Dec. 22: 9 a.m.-11 p.m.Dec. 23: 9 a.m.-10 p.m.Dec. 24 (Christmas Eve): 8 a.m.-6 p.m.Dec. 25 (Christmas Day): CLOSEDWestfield North County (272 E Via Rancho Parkway) 306

AURORA, Colo. – Hundreds of people are expected to gather Friday evening to demand that the officers involved in the in-custody death of Elijah McClain be fired by the Aurora Police Department.On Friday, they got part of their wish granted as Officer Jason Rosenblatt was among three Aurora Police officers fired. Rosenblatt recieved a text message from three other officers who imitated a choke hold that was performed on McClain. Rosenblatt responded with "Ha-Ha" to the text messages, Aurora Interim Police Chief Vanessa Wilson said. Two of the officers in the photo were fired, while a third resigned earlier this week. But the protesters are calling for the firing of two additional officers who were involved in last August's incident that resulted in McClain's death.“For 10 months Aurora Police Department has shielded Elijah McClain's murderers on their force from facing any form of justice. It was only last Friday, just ahead of a mass march for Elijah, that they pulled the three killers off the streets and put them on paid desk duty,” reads the announcement of the protest organized by the Party for Socialism and Liberation – Denver (PSL). “We need to make it clear that this is absolutely NOT enough.”Last Friday, APD announced officers Nathan Woodyard, Rosenblatt and Randy Roedema had been taken off street duty "because of threats and harassment," according to a police spokesperson. Police said those threats involved phone calls as well as email messages.Officials did not disclose which department the officers were reassigned to, but said they were working in a "non-enforcement capacity."The PSL says they expect murder charges “for the three killers” and demand that APD fire all three “IMMEDIATELY.”The rally will start at 3 p.m. MT at the site where organizers say, “Elijah was brutalized and killed and where APD danced on his grave.” From there, protesters will march to the APD headquarters at the Aurora Municipal Center.The rally will start three hours earlier than originally planned as McClain's family plans to hold a "community response" following a 2 p.m. news conference by the Aurora Police Department. The march is still scheduled for 6 p.m. The march and protest will put APD’s response to test once again, following a violent night of confrontation between officers and protesters last Saturday.Organizers say there will be people of all ages at Friday’s protest, “who do not want a repeat of last Saturday’s violence from APD, but (who) will not be intimidated out of exercising their First Amendment right to assemble and voice their concerns.”McClain’s death, largely unnoticed for the past 10 months, recently garnered national media attention following nationwide calls to reform interactions between police and Black Americans in the wake of George Floyd’s death.On Tuesday, the Colorado U.S. Attorney's Office, along with several other law enforcement agencies, announced they've been reviewing facts in the death of the 23-year-old Black man since last year for a potential federal civil rights investigation, saying they were aware of the photo allegations which surfaced Monday evening, and were gathering further information about the incident. This article was written by óscar Contreras for KMGH. 3275

DENVER — Pavilion M is just one of the almost two dozen buildings at Denver Health’s medical campus. From the outside it’s really nondescript, but it really is one of a kind. Inside is the 208

INDIANAPOLIS — The U.S. Food and Drug Administration on Monday granted emergency use authorization to Eli Lilly and Company's experimental COVID-19 antibody treatment bamlanivimab.According to a statement from the company, the drug is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test who are at high risk for progressing to severe COVID-19 and/or hospitalization. Lilly said in a statement the drug should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The authorization allows for the distribution and emergency use of bamlanivimab, which is administered via a single intravenous infusion."This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for recently diagnosed, high-risk patients — adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic," David A. Ricks, Lilly's chairman and CEO, said. "The rapid development and availability of bamlanivimab could not have been achieved without the relentless work of our Lilly team, collaboration across the industry and the urgent work being done by the government to ensure appropriate allocation to patients who need it the most."The emergency use authorization is based on data from BLAZE-1, a randomized, double-blind, placebo-controlled Phase 2 study in patients with recently diagnosed mild to moderate COVID-19 in the outpatient setting. Patients treated with the drug showed reduced viral load and rates of symptoms and hospitalization, Lilly said in the statement. Infusion reactions and other allergic hypersensitivity events have been reported, Lilly said. The emergency use authorization includes a warning for hypersensitivity including anaphylaxis and infusion-related reactions.Lilly said the drug is not authorized for use in patients who are hospitalized due to COVID-19 or who require oxygen therapy due to COVID-19 or who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity."The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus," Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories, said. "We're proud of the speed with which we have been able to bring patients this therapy specifically designed to treat COVID-19. We thank those who have contributed to this medical advancement, particularly the clinical trial investigators and participants around the country." This article was written by Bob Blake for WRTV. 2906

来源：资阳报